101 filings
8-K
EDIT
Editas Medicine Inc
14 Jun 24
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion
6:04am
8-K
EDIT
Editas Medicine Inc
31 May 24
Submission of Matters to a Vote of Security Holders
4:18pm
8-K
EDIT
Editas Medicine Inc
8 May 24
Editas Medicine Announces First Quarter 2024 Results and Business Updates
7:08am
8-K
EDIT
Editas Medicine Inc
28 Feb 24
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
7:06am
8-K
EDIT
Editas Medicine Inc
13 Dec 23
Regulation FD Disclosure
9:02am
8-K
9gr0kz3
11 Dec 23
Regulation FD Disclosure
4:23pm
8-K
bczsyo rtqhfpnx
22 Nov 23
Departure of Directors or Certain Officers
4:10pm
8-K
0kazuywaw hi
3 Nov 23
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
7:06am
8-K
e3n1l8kz
10 Oct 23
Departure of Directors or Certain Officers
4:05pm
8-K
paqi5nsrq uu02gnq25e
2 Aug 23
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
7:16am
8-K
vkg5wcbi5 wgt
15 Jun 23
Editas Medicine Announces Offering of Common Stock
4:30pm
8-K
5zkxl8qjc1k lc9g74k
9 Jun 23
Regulation FD Disclosure
6:01am
8-K
bvjf 99gh
5 Jun 23
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
syt48b8bbi6
17 May 23
Departure of Directors or Certain Officers
4:30pm
8-K
hjyql0t7g5obkfeiqyph
5 May 23
Editas Medicine Announces First Quarter 2023 Results and Business Updates
7:16am
8-K
rfmf3a2c72uj9xr4o
13 Apr 23
Departure of Directors or Certain Officers
5:09pm
8-K
7jlxr
14 Mar 23
Departure of Directors or Certain Officers
4:45pm
8-K
asshzobf96phc 2j45
22 Feb 23
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
6:31am
8-K
3o1t2 qy9wv2q
9 Jan 23
Departure of Directors or Certain Officers
8:36am
8-K
sclp9i5vmzbuflfbfq
6 Dec 22
Other Events
6:41am